<DOC>
	<DOCNO>NCT00003035</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give drug different way may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness doxorubicin paclitaxel treat woman locally advance breast cancer .</brief_summary>
	<brief_title>Doxorubicin Paclitaxel Treating Women With Locally Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess feasibility obtain serial biopsy patient receive neoadjuvant chemotherapy locally advance breast cancer . II . Assess feasibility perform assay apoptosis marker predict response specimen obtain patient . III . Correlate result assay clinical pathologic response rate . IV . Establish baseline change apoptosis rate future study . V. Obtain serial blood sample tumor tissue future biological study . OUTLINE : This randomize study . Patients stratify pre postmenopausal state T3 T4 lesion . Arm I : Patients receive single agent doxorubicin bolus infusion day 1 . Dose repeat every 14 day total four course , provide absolute neutrophil count ( ANC ) platelet count remain appropriate range . Patients receive paclitaxel IV administer 3 hour every 14 day total four course , provide ANC platelet count remain appropriate range . Filgrastim ( G-CSF ) subcutaneous treatment start day 3 course , continue 7 day , ANC great 10,000/mm3 . Patients undergo serial core-needle breast biopsy fine needle aspiration prior start therapy day one course . Arm II : Patients receive four course paclitaxel give every 14 day . Patients receive four course doxorubicin give day 1 every 14 day , provide ANC platelet count appropriate range . G-CSF subcutaneous treatment start day 3 course , Arm I . Patients undergo serial core-needle breast biopsy fine needle aspiration prior start day one course . Arm I II : Upon completion eight course chemotherapy , patient undergo surgical procedure evaluate extent residual disease number lymph node involve , achieve local control . Following surgery , patient receive additional treatment discretion treat oncologist . Eligible patient undergo high dose chemotherapy peripheral blood stem cell rescue ; patient receive cyclophosphamide therapy . Patients receive lumpectomy receive breast irradiation . Patients receive mastectomy might receive chest wall irradiation . Following radiotherapy , hormone receptor positive patient may start tamoxifen therapy 5 year . PROJECTED ACCRUAL : An estimated 40 patient ( 20 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally advanced breast cancer Unresected T3 T4 lesion , OR Unresected T2 lesion patient consider appropriate candidate neoadjuvant chemotherapy enhance breast conservation Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 02 Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal Renal : Creatinine great 1.5 time normal Cardiovascular : LVEF least 50 % ( baseline MUGA ) No history uncontrolled congestive heart failure At least 6 month since prior myocardial infarction No unstable angina No uncontrolled hypertension Neurologic : No peripheral neuropathy Other : Not pregnant nursing No psychosis PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic therapy Endocrine therapy : No prior hormonal therapy breast cancer Prior estrogen replacement therapy allow No concurrent steroid therapy Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent treatment serious infection ( bacterial , viral , fungal )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>